GlassScriptPhysician profile
Timothy James Dobin
NPI 1649624347
$11,607.33
in general payments reported to CMS, 2019-2025
34 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $526 · 2021: $948 · 2022: $1,064 · 2023: $1,767 · 2024: $3,289 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,069 · Grant: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,069.07 |
| Grant | $335.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,180.20 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,120.35 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,084.99 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $657.23 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $652.21 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $599.14 | 2021-2025 | |
| Ardelyx, INC. | $596.85 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $474.33 | 2020-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $449.79 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $334.26 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $308.02 | 2019-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $300.53 | 2019-2021 | |
| Celgene Corporation | $236.75 | 2023-2024 | Zeposia |
| Pfizer INC. | $225.71 | 2022-2025 | |
| Steris Corporation | $217.01 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $155.38 | 2024-2025 | Resmetirom, Rezdiffra |
| Novo Nordisk INC | $131.51 | 2022-2025 | Wegovy |
| Qol Medical, LLC | $126.94 | 2023-2024 | Sucraid, Sucraid |
| Boston Scientific Corporation | $108.57 | 2021 | |
| Ferring Pharmaceuticals INC. | $107.35 | 2023-2024 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $105.05 | 2022 | |
| Aimmune Therapeutics, INC. | $90.89 | 2024-2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $90.40 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $44.92 | 2023 | Idacio |
| Celltrion USA INC. | $35.24 | 2024 | Vegzelma |
| Redhill Biopharma INC. | $32.57 | 2023 | |
| Biocon Biologics INC | $20.86 | 2024 | Hulio |
| Shionogi INC | $17.62 | 2019 | |
| Ethicon US, LLC | $14.60 | 2021 | |
| Braintree Laboratories, INC. | $14.10 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.04 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.83 | 2023 | |
| Eisai INC. | $11.98 | 2020 | |
| Covidien LP | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Dobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.